Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and ...
Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results ...
Atossa Genetics (NasdaqCM: ATOS) is a medical diagnostics company focused on the prevention of breast cancer through the development and commercialization of diagnostic tests that can detect ...
ATOS READ THE FULL ATOS RESEARCH REPORT We are initiating coverage of Atossa Therapeutics, Inc. (NASDAQ:ATOS) with a valuation of $22.00. Atossa is a clinical-stage biopharmaceutical company that is ...
(RTTNews) - Atossa Therapeutics, Inc. (ATOS), a Washington-based biopharmaceutical company, has released a statement addressing the PTAB's final decision in PGR2023-00043 concerning U.S. Patent No. 11 ...
The MarketWatch News Department was not involved in the creation of this content. Recognized for Visionary Leadership and Advancing Innovative Therapies in Oncology and Healthcare Technology SEATTLE, ...
What To Know: The FDA granted one of the biopharmaceutical company’s potential treatments, (Z)-Endoxifen, a rare pediatric disease designation for the treatment of Duchenne Muscular Dystrophy. The ...
Atossa Genetics, a Seattle company that’s developing and marketing diagnostic tests for precursors to breast cancer, filed paperwork Tuesday to raise about $6 million in an initial public stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results